Biliary Tract Cancer
If it’s your first time on this website, please read the disclaimer section.
Jun 01 – Jun 08, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 3 randomized trial (FIGHT-302) evaluated the efficacy and safety of first-line pemigatinib compared to gemcitabine plus cisplatin chemotherapy in 167 adults with advanced FGFR2-rearranged cholangiocarcinoma. Pemigatinib significantly improved median progression-free survival to 8.3 months compared to 6.8 months for chemotherapy (HR 0.58; p=0.0078), with a notably higher objective response rate of 47% versus 15%. Although median overall survival was similar between groups (24.4 vs. 25.0 months), pemigatinib demonstrated a superior duration of response (14.2 vs. 6.3 months) with a safety profile consistent with previous findings. These results support pemigatinib as a potent first-line targeted therapy option for patients with this specific genetic rearrangement, offering a non-chemotherapeutic alternative with improved progression control.
10.1200/JCO-26-00788
Mar 02 – Mar 09, 2026
A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This study developed and validated a deep-learning pathology model (AI2CCA) to differentiate intrahepatic cholangiocarcinoma (ICCA) from metastatic liver cancers using retrospective data from 544 patients and prospective validation in 161 patients. The optimized model achieved an initial AUROC of 0.840, which improved to 0.958 with a zero false positive rate after implementing confidence thresholding, and maintained high prospective performance with AUROCs between 0.965 and 1.00. For clinicians, this tool addresses the diagnostic ambiguity of overlapping histological features, potentially eliminating the need for extensive exclusionary investigations like endoscopies. These findings suggest that confidence-based AI biomarkers can significantly accelerate therapeutic decision-making and reduce the financial burden of diagnosing lethal hepatobiliary malignancies.
10.1016/j.annonc.2026.02.018
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 2-3 randomized trial evaluated the efficacy of neoadjuvant GOLP (gemcitabine, oxaliplatin, lenvatinib, and toripalimab) followed by surgery compared to surgery alone in 178 patients with high-risk resectable intrahepatic cholangiocarcinoma. The neoadjuvant group demonstrated a significantly longer median event-free survival of 18.0 months compared to 8.7 months in the control group (P<0.001), with a 24-month overall survival rate of 79% versus 61%. For clinicians focused on oncology, this study provides high-level evidence for a novel intensive neoadjuvant strategy in a cancer type that currently lacks established standard preoperative protocols. While grade 3 or higher adverse events occurred in 28% of the neoadjuvant cohort, the substantial improvement in survival outcomes suggests GOLP is a viable and effective treatment option for high-risk surgical candidates.
10.1056/NEJMoa2513918
Perioperative approaches for patients with biliary tract cancer.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review examines evolving perioperative strategies for biliary tract cancers, including cholangiocarcinoma and gallbladder cancer, focusing on the integration of surgery, transplantation, and systemic therapies. While specific numerical trial results are not detailed in this abstract, it highlights that most patients present with unresectable disease and emphasizes the shift toward using immune-checkpoint inhibitors and targeted therapies in earlier-stage settings. The study directly addresses the clinician’s interest in cancer by detailing multidisciplinary management and individualized treatment algorithms for these aggressive malignancies. Future clinical practice will likely rely on biomarker-driven strategies and molecular profiling to optimize patient selection for surgery and systemic therapy, necessitating global collaboration in trial design.
10.1038/s41571-026-01130-5